SAFETY AND EFFICACY OF PROPROTEIN CONVERTASE SUBTILISIN/ KEXIN TYPE 9 INHIBITORS AFTER ACUTE CORONARY SYNDROME; A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

被引：0
|
作者：
Atia, A. [1 ,2 ]
Wageeh, A. [3 ]
Aboeldahab, H. [4 ]
Elneny, M. [5 ]
Abdelwahab, M. [6 ]
Elmallahy, M.
Aboelkhier, M. [7 ,8 ]
Elawfi, B. [9 ]
Sayed, S. [10 ]
Elrosasy, A. [1 ]
机构：
[1] Cairo Univ, Cardiol, Fac Med, Cairo, Egypt
[2] Med Res Grp Egypt, Cardiol, Cairo, Egypt
[3] Menoufia Univ, Cardiol, Fac Med, Menoufia, Egypt
[4] Alexandria Univ, Med Res Inst, Biomed Informat & Med Stat Dept, Biomed Informat & Med Stat, Alexandria, Egypt
[5] Al Azhar Univ, Damietta Fac Med, Cardiol, Dumyat, Egypt
[6] Helwan Univ, Cardiol, Fac Med, Cairo, Egypt
[7] Tanta Univ, Cardiol, Fac Med, Tanta, Egypt
[8] Suez Canal Univ, Master Program, Sci, Fac Sci, Ismailia, Egypt
[9] Sanaa Univ, Cardiol, Fac Med, Sanaa, Yemen
[10] Minia Univ, Cardiol, Fac Med, Al Minya, Egypt
来源：
ATHEROSCLEROSIS | 2023年 / 379卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P248
引用
收藏
页码：S78 / S80
页数：2
相关论文
共 50 条
  • [31] Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia A Systematic Review and Meta-analysis
    Navarese, Eliano Pio
    Kolodziejczak, Michalina
    Schulze, Volker
    Gurbel, Paul A.
    Tantry, Udaya
    Lin, Yingfeng
    Brockmeyer, Maximilian
    Kandzari, David E.
    Kubica, Julia M.
    D'Agostino, Ralph B., Sr.
    Kubica, Jacek
    Volpe, Massimo
    Agewall, Stefan
    Kereiakes, Dean J.
    Kelm, Melte
    ANNALS OF INTERNAL MEDICINE, 2015, 163 (01) : 40 - 51
  • [32] Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis
    Vlachopoulos, Charalambos
    Terentes-Printzios, Dimitrios
    Georgiopoulos, Georgios
    Skoumas, Ioannis
    Koutagiar, Iosif
    Ioakeimidis, Nikolaos
    Stefanadis, Christodoulos
    Tousoulis, Dimitrios
    ATHEROSCLEROSIS, 2016, 252 : 50 - 60
  • [33] Proprotein convertase subtilisin/kexin type 9 inhibitors in peripheral artery disease: A review of efficacy, safety, and outcomes
    Mohyeldin, Moiud
    Abuelgasim, Ahmed S.
    Mustafa, Ahmed M. G.
    WORLD JOURNAL OF CARDIOLOGY, 2024, 16 (07):
  • [34] Circulating Levels of Proprotein Convertase Subtilisin Kexin Type 9 are Elevated by Fibrate Therapy A Systematic Review and Meta-Analysis of Clinical Trials
    Sahebkar, Amirhossein
    CARDIOLOGY IN REVIEW, 2014, 22 (06) : 306 - 312
  • [35] Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Ezetimibe on Risk of New-Onset Diabetes: A Systematic Review and Meta-Analysis of Large, Double-Blinded Randomized Controlled Trials
    Chiu, Sarah W.
    Pratt, Cristina M.
    Feinn, Richard
    Chatterjee, Saurav
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2020, 25 (05) : 409 - 417
  • [36] Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction
    Schwartz, Gregory G.
    Giugliano, Robert P.
    CURRENT OPINION IN LIPIDOLOGY, 2022, 33 (03) : 147 - 159
  • [37] Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia
    Dijk, Wieneke
    Cariou, Bertrand
    DIABETES OBESITY & METABOLISM, 2019, 21 : 39 - 51
  • [38] Prediction of cardiovascular events with plasma proprotein convertase subtilisin/kexin type 9 levels: a systematic review and meta-analysis
    Terentes-Printzios, D.
    Vlachopoulos, C.
    Ioakeimidis, N.
    Pietri, P.
    Skliros, N.
    Tousoulis, D.
    EUROPEAN HEART JOURNAL, 2016, 37 : 138 - 139
  • [39] Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression
    Rivera, Frederick Berro
    Cha, Sung Whoy
    Magalong, John Vincent
    Bantayan, Nathan Ross B.
    Cruz, Linnaeus Louisse A.
    Arias-Aguirre, Eloise
    Aguirre, Zedrick
    Varona, Michelle Capahi
    Co, Elaiza Marie Fernandez
    Lumbang, Grace Nooriza Opay
    Enkhmaa, Byambaa
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (07) : 1103 - 1121
  • [40] Barriers to prescribing proprotein convertase subtilisin-kexin type 9 inhibitors after coronary revascularisation
    Nguy, Jenny
    Hitchen, Sarah A.
    Lan, Nick S. R.
    Dwivedi, Girish
    Larbalestier, Robert
    Yeap, Bu B.
    Fegan, P. Gerry
    INTERNAL MEDICINE JOURNAL, 2023, 53 (06) : 994 - 1001
12345